

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 September 2000 (21.09.2000)

PCT

(10) International Publication Number  
**WO 00/55624 A3**

(51) International Patent Classification<sup>7</sup>: G01N 33/53,  
33/543, C07D 473/08, 473/10, 473/12

(21) International Application Number: PCT/CA00/00246

(22) International Filing Date: 9 March 2000 (09.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/124,488 15 March 1999 (15.03.1999) US

(71) Applicants and

(72) Inventors: LEYLAND-JONES, Brian [CA/CA]; 7816  
Bodinier, Anjou, Québec H1K 4C5 (CA). WONG, Pierre  
[CA/CA]; Apartment 4, 3415 Aylmer, Montréal, Québec  
H2X 2B4 (CA).

(74) Agents: CÔTÉ, France et al.; Swabey Ogilvy Renault,  
1981 McGill College Avenue, Suite 1600, Montréal,  
Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:  
1 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/55624 A3

(54) Title: ELISA KIT FOR THE DETERMINATION OF METABOLIC PHENOTYPES

(57) Abstract: The invention relates to an enzyme linked immunosorbent assay (ELISA) kit for the rapid determination of metabolic phenotypes including but not limited to CYP 1A2, N-acetyltransferase-1 (NAT-1), CYP 2P6, CYP 2E1 and CYP 3A4, which can be used on a routine basis in a clinical laboratory. The ELISA kit allows physicians to a) individualize therapy of drugs such as theophylline, tamoxifen, and clozapine and b) to predict susceptibility to carcinogen induced diseases such as colon rectal cancers. To reduce the number of patients undergoing clinical testing by selecting for patients with the appropriate phenotype most likely to respond.